L-Prolinamide, N-(10-carboxy-1-oxodecyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- manufacturers
|
| | L-Prolinamide, N-(10-carboxy-1-oxodecyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- Basic information |
| | L-Prolinamide, N-(10-carboxy-1-oxodecyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- Chemical Properties |
| Boiling point | 897.0±65.0 °C(Predicted) | | density | 1.205±0.06 g/cm3(Predicted) | | pka | 4.78±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | L-Prolinamide, N-(10-carboxy-1-oxodecyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- Usage And Synthesis |
| Description | MDN19780 is a Functionalized von-Hippel-Lindau protein (VHL) ligand for PROTAC research and development. It incorporates an E3 ligase ligand plus an alkylC9 linker with terminal carboxylic acid ready for conjugation to a target protein ligand. MDN19780 is Part of a range of functionalized tool molecules for PROTAC R&D. This product has no formal name. | | Uses | (S,R,S)-AHPC-CO-C9-acid is an E3 ligase ligand-linker conjugate that can be connected to the ligand for protein to form PROTACs. | | storage | Store at -20°C | | References | [1] Xu J, et al. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discov. 2021 Jul 23. DOI:10.1158/2159-8290.CD-20-0815 |
| | L-Prolinamide, N-(10-carboxy-1-oxodecyl)-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)- Preparation Products And Raw materials |
|